Four University of Bristol academics have achieved the rare distinction of being elected Fellows of the world’s most eminent and oldest scientific academy in continuous existence, the Royal Society.
A new consortium to accelerate the discovery of novel drugs to treat kidney diseases is announced today [Monday 6 November]. The NEPLEX (nephron on a chip with cellular and extracellular matrix complexity) consortium, comprising leading academic institutions including the Universities of Bristol and Cambridge, and Evotec AG, will combine key technologies to develop and build a novel drug discovery device ("Nephron-on-a-Chip").
A new drug combination that could help thousands of children with arthritis and prevent them from serious complications, including blindness, has been discovered by researchers and thanks to a trial funded by Arthritis Research UK and the National Institute for Health Research (NIHR).
A collaborative team of researchers is to develop a wearable robotic system for minimally invasive surgery, also known as keyhole surgery, that will offer surgeons natural and dexterous movement as well as the ability to ‘sense’, ‘see’, control and safely navigate through the surgical environment.
Researchers from the Bristol Medical School have found that there is no evidence that any of the newer hip implant combinations, such as ceramic or uncemented, are better than the widely used small head metal-on-plastic cemented hip combination, which has been commonly used since the 1960s.
A new resource designed to support women experiencing domestic violence and abuse has been launched on the HealthTalk charity website today. The resource, developed by researchers from the Universities of Bristol and Oxford with funding from the NIHR Research for Patient Benefit Programme, includes over 30 video- and audio-recorded interviews with women who describe a range of abuse, including physical, emotional, financial and sexual abuse, and coercive and controlling behaviour, which became a criminal offence in 2015.
Eye injection drugs recommended by NICE cost the NHS up to £447 million annually, but could be replaced by an unlicensed drug, bevacizumab, costing as much as ten times less. Use of the two licensed drugs, ranibizumab and aflibercept, has increased three-fold over the last five years, with some parts of England treating five times as many patients as others.
Inviting men with no symptoms to a one-off PSA* test for prostate cancer does not save lives according to results from the largest ever trial conducted by Cancer Research UK-funded scientists based at the University of Bristol.
The National Child Mortality Database (NCMD) Programme, which was established on 1 April 2018 with the aim of reducing premature mortality by collecting and analysing data on all deaths in children in England, aged between birth and their 18th birthday, has published its first annual report [10 Oct 2019].
A team of researchers based at three Universities, including the University of Bristol, are working with the National Institute for Health Research (NIHR) to help people who may be lonely in our communities.
